title: ODYSSEY ESCAPE: is PCSK9 inhibition the Trojan Horse for the use of lipoprotein apheresis in familial hypercholesterolaemia?
authors.affiliation: School of Medicine and Pharmacology, University of Western Australia, Western Australia, Australia gerald.watts@uwa.edu.au.|Lipid Disorders Clinic, Department of Cardiology, Royal Perth Hospital, Western Australia, Australia.
authors.forename: Gerald F
authors.initials: GF
authors.lastname: Watts
authors.affiliation: Extracorporeal Therapeutic Techniques Unit, Immunohematology and Transfusion Medicine, Lipid Clinic and Atherosclerosis Prevention Centre, 'Umberto I' Hospital, Rome, Italy.|Department of Molecular Medicine, 'Sapienza', University of Rome, Rome, Italy.
authors.forename: Claudia
authors.initials: C
authors.lastname: Stefanutti
mesh_terms: D001781:Blood Component Removal; D008078:Cholesterol, LDL; D006801:Humans; D006938:Hyperlipoproteinemia Type II; D008074:Lipoproteins; D000071449:Proprotein Convertase 9
chemical_list: D008078:Cholesterol, LDL; D008074:Lipoproteins; C472125:PCSK9 protein, human; D000071449:Proprotein Convertase 9